One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
ﻗﯿﻤﺖ : 300$- ﻗﯿﻤﺖ ﻭﯾﮋﻩ : 100$
Antibody-Based Therapies for the Treatment of Hodgkin Lymphoma in Older Patients.
doi : 10.1200/JCO-25-01022
Volume 43(27) pgs. 2955-3056 September 20, 2025
Modern Targeted Radiation in Patients With Brain Metastases From Small Cell Lung Cancer.
doi : 10.1200/JCO-25-01259
Reading the Room: A Joint Perspective From a Scientist- and Patient-Partnered Working Group on the Importance of Patient-Centered Language in the Dissemination of Cancer Research.
doi : 10.1200/JCO-25-00186
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.
doi : 10.1200/JCO-25-00204
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.
doi : 10.1200/JCO-25-00439
Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial.
doi : 10.1200/JCO-25-00056
Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
doi : 10.1200/JCO-25-00385
Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms Among Childhood Cancer Survivors: A Report From the Children's Oncology Group ALTE03N1 Study.
doi : 10.1200/JCO-25-00542
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.
doi : 10.1200/JCO-25-00363
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
doi : 10.1200/JCO-25-00618
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
doi : 10.1200/JCO-25-01767
